Get the Stockscreener App
2.15
0.92%
-0.02
After Hours:
2.14
-0.010
-0.47%
Okyo Pharma Limited stock is traded at $2.15, with a volume of 41,195.
It is down -0.92% in the last 24 hours and down -27.43% over the past month.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$2.17
Open:
$2.2
24h Volume:
41,195
Relative Volume:
0.24
Market Cap:
$80.86M
Revenue:
-
Net Income/Loss:
$-13.27M
P/E Ratio:
-13.11
EPS:
-0.164
Net Cash Flow:
$-7.70M
1W Performance:
-4.87%
1M Performance:
-27.43%
6M Performance:
+42.38%
1Y Performance:
+107.73%
1-Day Range:
$2.12
$2.3936
1-Week Range:
$2.11
$2.3936
52-Week Range:
$0.9016
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
2.15 | 81.99M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Okyo Pharma Limited Stock (OKYO) Latest News
Will OKYO Pharma Limited see short term momentum2025 Top Decliners & Fast Gain Swing Trade Alerts - Newser
will okyo pharma limited stock go up soonQuarterly Portfolio Summary & Daily Chart Pattern Signals - Newser
How to forecast OKYO Pharma Limited trends using time seriesChart Signals & AI Optimized Trading Strategy Guides - Newser
Will OKYO Pharma Limited stock go up soonJuly 2025 PostEarnings & Safe Capital Investment Plans - Newser
Applying sector rotation models to OKYO Pharma LimitedJuly 2025 Momentum & Daily Chart Pattern Signals - Newser
Analyzing drawdowns of OKYO Pharma Limited with statistical tools2025 Retail Activity & Low Risk Entry Point Tips - Newser
Multi asset correlation models including OKYO Pharma Limited2025 Volatility Report & Low Drawdown Momentum Trade Ideas - Newser
What’s next for OKYO Pharma Limited stock pricePortfolio Return Report & Entry and Exit Point Strategies - Newser
Intraday pattern recognizer results for OKYO Pharma Limited2025 Macro Impact & Fast Entry Momentum Alerts - Newser
How to track smart money flows in OKYO Pharma LimitedStop Loss & Daily Entry Point Trade Alerts - Newser
Can OKYO Pharma Limited recover in the next quarterMarket Risk Report & Safe Entry Momentum Tips - Newser
OKYO Pharma Limited stock momentum explainedPortfolio Growth Summary & Low Drawdown Trading Techniques - Newser
Real time breakdown of OKYO Pharma Limited stock performanceJuly 2025 Levels & Risk Controlled Daily Plans - Newser
Does OKYO Pharma Limited fit your quant trading modelRecession Risk & Verified Chart Pattern Trade Signals - Newser
Is it time to cut losses on OKYO Pharma LimitedJuly 2025 Intraday Action & Capital Efficient Trading Techniques - Newser
How to escape a deep drawdown in OKYO Pharma LimitedJuly 2025 Fed Impact & Weekly High Return Stock Forecasts - Newser
OKYO Pharma Limited recovery potential after sell offMarket Performance Recap & Expert Verified Movement Alerts - Newser
What to do if you’re stuck in OKYO Pharma LimitedEarnings Beat & AI Optimized Trade Strategies - Newser
What earnings revisions data tells us about OKYO Pharma LimitedJuly 2025 Pullbacks & Weekly High Conviction Trade Ideas - Newser
Applying Wyckoff theory to OKYO Pharma Limited stockWeekly Investment Report & Expert Curated Trade Ideas - Newser
Will OKYO Pharma Limited benefit from government policyJuly 2025 PostEarnings & High Win Rate Trade Tips - Lancaster City Council
Is OKYO Pharma Limited still worth holding after the dip2025 Major Catalysts & Real-Time Volume Spike Alerts - Newser
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):